Nashville-based BehaVR inks potential $140 million deal with Japanese pharmaceutical company

The deal, with Osaka-based Sumitomo Dainippon Pharma Co., is for the companies to develop and commercialize prescription digital therapies and general wellness products for the treatment of anxiety disorders.

Source: bizjournals.com Health Care:Biotechnology headlines - October 18, 2021 Category: Biotechnology Authors: Joel Stinnett Source Type: news